Dekker E, Tanis PJ, Vleugels JLA et al (2019) Colorectal cancer. Lancet 394:1467–1480

Article  PubMed  Google Scholar 

Li J, Ma X, Chakravarti D et al (2021) Genetic and biological hallmarks of colorectal cancer. Genes Dev 38:787–820

Article  Google Scholar 

Stintzing S (2014) Management of colorectal cancer. F1000Prime Rep. https://doi.org/10.1270/P6-108

Article  PubMed  PubMed Central  Google Scholar 

Glynne-Jones R, Wyrwicz L, Tiret E et al (2017) Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:22–40. https://doi.org/10.1093/annonc/mdx224

Article  Google Scholar 

Feeney G, Sehgal R, Sheehan M et al (2019) Neoadjuvant radiotherapy for rectal cancer management. World J Gastroenterol 25:4850–4869

Article  PubMed  PubMed Central  Google Scholar 

van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386–1422. https://doi.org/10.1093/annonc/mdw235

Article  PubMed  Google Scholar 

Heidelberger C, Chaudhuri NK, Danneberg P et al (1957) Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179:663–666. https://doi.org/10.1038/179663A0

Article  CAS  PubMed  Google Scholar 

Vodenkova S, Buchler T, Cervena K et al (2020) 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther 206:107447

Article  CAS  PubMed  Google Scholar 

Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27:23–44. https://doi.org/10.1016/J.CLINTHERA.2005.01.005

Article  CAS  PubMed  Google Scholar 

Grem JL (2000) 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 18:299–313. https://doi.org/10.1023/A:1006416410198

Article  CAS  PubMed  Google Scholar 

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE—Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr 112:90–92. https://doi.org/10.1016/J.AD.2019.05.009

Article  CAS  PubMed  Google Scholar 

Diasio RB (2001) Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology (Williston Park) 15:21–26

CAS  PubMed  Google Scholar 

Milano G, McLeod HL (2000) Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer 36:37–42. https://doi.org/10.1016/S0959-8049(99)00211-7

Article  CAS  PubMed  Google Scholar 

Amstutz U, Henricks LM, Offer SM et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210–216. https://doi.org/10.1002/CPT.911

Article  CAS  PubMed  Google Scholar 

Lunenburg CATC, van der Wouden CH, Nijenhuis M et al (2019) Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines. Eur J Human Genet 28(4):508–517. https://doi.org/10.1038/s41431-019-0540-0

Article  CAS  Google Scholar 

Amstutz U, Froehlich TK, Largiadr CR (2011) Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12:1321–1336. https://doi.org/10.2217/PGS.11.72

Article  CAS  PubMed  Google Scholar 

Mattison LK, Soong R, Diasio RB (2002) Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3:485–492. https://doi.org/10.1517/14622416.3.4.485

Article  CAS  PubMed  Google Scholar 

Lee AM, Shi Q, Pavey E et al (2014) DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. https://doi.org/10.1093/JNCI/DJU298

Article  PubMed  PubMed Central  Google Scholar 

del Re M, Cinieri S, Michelucci A et al (2019) DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenom J 19:556–563. https://doi.org/10.1038/S41397-019-0077-1

Article  Google Scholar 

Iachetta F, Bonelli C, Romagnani A et al (2019) The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study. Br J Cancer 120:834–839. https://doi.org/10.1038/S41416-019-0423-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Božina N, Bilić I, Ganoci L et al (2022) DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. Br J Clin Pharmacol 88:2190–2202. https://doi.org/10.1111/BCP.15144

Article  PubMed  Google Scholar 

EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine | European Medicines Agency. https://www.ema.europa.eu/en/news/ema-recommendations-dpd-testing-prior-treatment-fluorouracil-capecitabine-tegafur-flucytosine. Accessed 21 Feb 2023

Nota Informativa Importante su Medicinali contenenti 5-fluorouracile (i.v.), capecitabina e tegafur. https://www.aifa.gov.it/en/-/nota-informativa-importante-su-medicinali-contenenti-5-fluorouracile-i-v-capecitabina-e-tegafur. Accessed 21 Feb 2023

Linee guida e raccomandazioni RACCOMANDAZIONI PER ANALISI FARMACOGENETICHE | SIF. https://www.sifweb.org/pubblicazioni/linee-guida-e-raccomandazioni/linee-guida-e-raccomandazioni-raccomandazioni-per-analisi-farmacogenetiche-2020-08-31. Accessed 21 Feb 2023

Deenen MJ, Tol J, Burylo AM et al (2011) Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 17:3455–3468. https://doi.org/10.1158/1078-0432.CCR-10-2209

Article  CAS  PubMed  Google Scholar 

Terrazzino S, Cargnin S, del Re M et al (2013) DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 14:1255–1272. https://doi.org/10.2217/PGS.13.116

Article  CAS  PubMed  Google Scholar 

Deenen MJ, Meulendijks D, Cats A et al (2016) Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 34:227–234. https://doi.org/10.1200/JCO.2015.63.1325

Article  CAS  PubMed  Google Scholar 

Henricks LM, Lunenburg CATC, Meulendijks D et al (2015) Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics 16:1277–1286. https://doi.org/10.2217/PGS.15.70

Article  CAS  PubMed  Google Scholar 

Giorgio E, Caroti C, Mattioli F et al (2011) Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation. Cancer Chemother Pharmacol 68:1355–1361. https://doi.org/10.1007/S00280-011-1709-6

Article  CAS  PubMed  Google Scholar 

CPIC® Guideline for Fluoropyrimidines and DPYD – CPIC. https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/. Accessed 21 Feb 2023

Boige V, Vincent M, Alexandre P et al (2016) DPYD genotyping to predict adverse events following treatment with fluorouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial. JAMA Oncol 2:655. https://doi.org/10.1001/JAMAONCOL.2015.5392

Article  PubMed  Google Scholar 

Ruzzo A, Graziano F, Galli F et al (2017) Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer 117:1269–1277. https://doi.org/10.1038/BJC.2017.289

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deenen MJ, Tol J, Burylo AM et al (2011) Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-10-2209. Accessed 21 Feb 2023

Article  PubMed  Google Scholar